Elevated serum CA 125 levels in mitral stenotic patients with heart failure

Cardiology

Volumn 100, Issue 1, 2003, Pages 7-10

  Duman, Can ^a   Ercan, Ertugrul ^b,d   Tengiz, Istemihan ^b   Bozdemir, Huseyin ^c   Ercan, H Ekin ^b   Nalbantgil, Istemi ^c  

^a KOCAELI UNIVERSITY   (Turkey)

^b Central Hospital Izmir   (Turkey)

^c EGE UNIVERSITY   (Turkey)

^d Central Hospital   (Turkey)

Author keywords

CA 125; Mitral stenosis; Tumor markers

Indexed keywords

CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; ARTERY DIAMETER; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HEART FAILURE; HEART LEFT ATRIUM; HEART RIGHT ATRIUM; HEMODYNAMIC MONITORING; HUMAN; LUNG CAPILLARY PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MESOTHELIUM; MITRAL VALVE; MITRAL VALVE STENOSIS; PRESSURE GRADIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; STATISTICAL ANALYSIS;

CA-125 ANTIGEN; CARDIAC OUTPUT, LOW; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE STENOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0141453414     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000072385     Document Type: Article

References (13)

1. Bates SE: Clinical applications of serum tumor markers. Ann Intern Med 1991;115:623-638.
2. Fritsche HA: Serum tumor markers for patient monitoring: A case-oriented approach illustrated with carcinoembryonic antigen. Clin Chem 1993;39:2431-2434.
3. Fabris C, Falleti E, Pirisi M, Soardo G, Toniutto P, Vitulli D, Bortolotti N, Gonano F, Bartoli E: Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease associated with increased circulating levels of adhesion molecules. Clin Chim Acta 1995;243:25-33.
4. Wood WG, Werner A: CEA, TPA and CA 125 levels in different patient groups with benign and malignant disease. Arztl Lab 1984;30:309-315.
5. Cases A, Filella X, Molina R, Ballesta AM, Lopez-Pedret J, Revert L: Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991;57:183-186.
6. Collazos J: Clinical and laboratory evolution of CA 19-9 in cirrhotic patients. Eur J Med 1992;1:215-218.
7. Kenemans P, Yedema CA, Bon GG: CA 125 in gynecological pathology: A review. Eur J Obstet Gynecol Reprod Biol 1993;49:115-124.
8. Van der Burg ME, Lammes FB, Verweij J: CA 125 in ovarian cancer. Neth J Med 1992;40:36-51.
9. Hopman EH, Helmerhorst TJ, Bonfrer JM, Ten Bokkel Huinink WW: Highly elevated serum CA 125 levels in a patient with cardiac failure. Eur J Obstet Gynecol Reprod Biol 1993;48:71-73.
10. Nägele H, Bahlo M, Klapdor R, Schaeperkoetter D, Rödiger W: CA 125 and its relation to cardiac function. Am Heart J 1999;137:1044-1049.
11. Seo T, Ikeda Y, Onaka H: Usefulness of serum CA 125 measurement for monitoring pericardial effusion. Jpn Circ J 1993;57:489-494.
12. Toshihiko S, Megumi U, Takahiro H: Serum CA 125 measurement is useful in three cases with pericardial effusions. Kokyu To Junkan 1993;41:389-392.
13. Apel RL, Fernandes BJ: Malignant lymphoma presenting with an elevated serum CA 125 level. Pathol Lab Med 1995;119:373-376.